On 25 March 2026, Suzhou Ribo Life Science Co., Ltd. (Ribo Life Science) announced senior management changes aimed at strengthening its global clinical and commercial operations. Dr. Anders Gabrielsen has been appointed Chief Medical Officer (CMO), and Dr. John Taylor has been appointed Chief Business Officer (CBO), both effective the same day.

Dr. Gabrielsen, aged 59, will oversee clinical development, medical affairs, and regulatory compliance. He joined Ribo Life Science in 2023 as Vice President and Head of Global Clinical Development after more than 20 years in cardiovascular, renal, and metabolic therapeutics. His prior experience includes physician-scientist and executive roles at Bayer AG, Novartis AG, and AstraZeneca PLC between 2011 and 2023. Dr. Gabrielsen holds an M.D. and DMSc from the University of Copenhagen and completed postdoctoral research at the Karolinska Institute.

Dr. Taylor, aged 56, will lead global business development, including in-licensing, out-licensing, collaborations, and strategic investments. He joined the company in 2023 as Vice President and Head of Global Business Development. With more than 20 years in the biopharmaceutical industry, Dr. Taylor’s background spans scientific research and corporate transactions, featuring senior roles at Pfizer Inc. (1993–2003) and AstraZeneca PLC (2004–2023). He earned a Ph.D. in Biochemistry from the University of Bristol and conducted postdoctoral research at Duke University.

As part of the leadership transition, Dr. Gan Liming has stepped down from the CMO role but will continue as Executive Director, Co-Chief Executive Officer, and Global R&D President.

The Board extended a formal welcome to both executives as they assume their new positions.